chr6-89221200-T-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001267582.2(GABRR1):c.-242+75A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.358 in 152,098 control chromosomes in the GnomAD database, including 10,262 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.36 ( 10241 hom., cov: 31)
Exomes 𝑓: 0.39 ( 21 hom. )
Consequence
GABRR1
NM_001267582.2 intron
NM_001267582.2 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.472
Publications
5 publications found
Genes affected
GABRR1 (HGNC:4090): (gamma-aminobutyric acid type A receptor subunit rho1) GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA receptors, which are ligand-gated chloride channels. GABRR1 is a member of the rho subunit family. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2012]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.94).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.445 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.358 AC: 54230AN: 151682Hom.: 10234 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
54230
AN:
151682
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.389 AC: 116AN: 298Hom.: 21 AF XY: 0.400 AC XY: 72AN XY: 180 show subpopulations
GnomAD4 exome
AF:
AC:
116
AN:
298
Hom.:
AF XY:
AC XY:
72
AN XY:
180
show subpopulations
African (AFR)
AF:
AC:
2
AN:
6
American (AMR)
AF:
AC:
0
AN:
2
Ashkenazi Jewish (ASJ)
AF:
AC:
1
AN:
2
East Asian (EAS)
AC:
0
AN:
0
South Asian (SAS)
AF:
AC:
0
AN:
2
European-Finnish (FIN)
AF:
AC:
46
AN:
110
Middle Eastern (MID)
AF:
AC:
0
AN:
2
European-Non Finnish (NFE)
AF:
AC:
65
AN:
164
Other (OTH)
AF:
AC:
2
AN:
10
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.511
Heterozygous variant carriers
0
3
6
10
13
16
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.357 AC: 54264AN: 151800Hom.: 10241 Cov.: 31 AF XY: 0.352 AC XY: 26130AN XY: 74178 show subpopulations
GnomAD4 genome
AF:
AC:
54264
AN:
151800
Hom.:
Cov.:
31
AF XY:
AC XY:
26130
AN XY:
74178
show subpopulations
African (AFR)
AF:
AC:
18622
AN:
41348
American (AMR)
AF:
AC:
3555
AN:
15256
Ashkenazi Jewish (ASJ)
AF:
AC:
869
AN:
3466
East Asian (EAS)
AF:
AC:
489
AN:
5172
South Asian (SAS)
AF:
AC:
1306
AN:
4818
European-Finnish (FIN)
AF:
AC:
3868
AN:
10526
Middle Eastern (MID)
AF:
AC:
89
AN:
292
European-Non Finnish (NFE)
AF:
AC:
24432
AN:
67900
Other (OTH)
AF:
AC:
693
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1722
3444
5165
6887
8609
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
520
1040
1560
2080
2600
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
911
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.